The second study, instead, shows that among subjects with humoral immunodeficiencies requiring gamma–globulin replacement therapy, patients with bronchiectasis were found to have lower median levels of AAT than those without bronchiectasis [17], suggesting that a deficiency of AAT could promote the development of bronchiectasis. This evidence concerns the gene SERPINA1 and bronchiectasis.